Ziprasidone in schizophrenia

Harrigan E, Morrissey M, and the Ziprasidone Working Group. The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/schizoaffective disorder. Presented at the XXth Collegium Internationale Neuropsychopharmacologicum, Melbourne, Australia, June 1996. [Pg.95]

Gunasekara NS, Spencer CM, Keating GM. Spotiight on ziprasidone in schizophrenia and schizoaffective disorder. CNS Drugs 2002 16 645-52. [Pg.520]

Moteshafi H, Stip E. Comparing tolerability profQe of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders a meta-analysis. Expert Opin Drug Saf 2012 ll(5) 713-32. [Pg.77]

See also in sourсe #XX -- [ Pg.56 , Pg.554 , Pg.555 , Pg.555 , Pg.556 , Pg.563 ]

See also in sourсe #XX -- [ Pg.800 , Pg.810 ]

See also in sourсe #XX -- [ Pg.447 , Pg.448 ]

See also in sourсe #XX -- [ Pg.800 , Pg.810 ]

See also in sourсe #XX -- [ Pg.1214 , Pg.1215 , Pg.1216 , Pg.1221 , Pg.1222 , Pg.1223 , Pg.1224 , Pg.1225 , Pg.1226 , Pg.1227 , Pg.1228 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...